Clinical trial
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of…
NCT04501952 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT04501952 |
|---|---|
| Title | Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting |
| Official title | A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | COVID-19 |
| Intervention type | Drug |
| Interventions | RDV, Placebo to Match RDV |
| Enrollment | 584 |
| Start date | Sep 18, 2020 |
| Primary completion | May 6, 2021 |
| Completion | May 6, 2021 |
| First posted | Aug 6, 2020 |
| Last update posted | Nov 16, 2021 |
| Countries | Denmark, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: